{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-26-001743","form_type":"8-K","ticker":"TLSI","cik":"0001826667","company_name":"TriSalus Life Sciences, Inc.","filed_at":"2026-01-12T23:59:59+00:00","discovered_at":"2026-05-14T18:02:36.387606+00:00","generated_at":"2026-05-16T10:56:35.977636+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"TriSalus reports Q4 revenue $13.2M (+60% YoY), FY25 $45.2M (+53%), FY26 guidance $60-62M","bullets":["Q4 2025 revenue approx $13.2M vs $8.3M year ago, up 60% YoY; full-year revenue approx $45.2M vs $29.4M, up 53% YoY.","Revenue growth exceeded prior guidance of 50% annual growth for 2025.","Initial 2026 revenue guidance set at $60M to $62M.","Year-end cash approx $20.4M, down $2.3M from start of Q4 reflecting investment in growth."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-26-001743","json":"https://secwatch.observer/filing/0001628280-26-001743.json","markdown":"https://secwatch.observer/filing/0001628280-26-001743.md","text":"https://secwatch.observer/filing/0001628280-26-001743.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1826667/000162828026001743/0001628280-26-001743-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1826667/000162828026001743/tlsi-20260112.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T10:56:35.977636+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}